TAS::75 0849::TAS

洛杉矶SEER残留组织库（RTR）将为研究目的提供基于组织的资源，包括来自艾滋病毒/艾滋病患者的癌症肿瘤标本和来自多肿瘤块的非艾滋病毒/艾滋病患者的类似癌症肿瘤标本。艾滋病毒/艾滋病患者将从以前的洛杉矶县卫生服务部艾滋病毒/艾滋病和南加州大学癌症监测项目数据库链接中识别，也将从明年提出的新链接中识别。目标是收集970名癌症患者的生物标本。以下类型的癌症样本将作为艾滋病毒/艾滋病病例的目标：黑色素瘤（n-30）、霍奇金淋巴瘤（n=30）、非霍奇金淋巴瘤（n=200）、肺癌（n=50）、宫颈癌（n=40）和肛门癌（n=40）。除非霍奇金淋巴瘤患者外，未感染艾滋病毒/艾滋病但癌症相似的癌症患者也将选择以2:1匹配比例进行比较，但非霍奇金淋巴瘤也将选择以1:1匹配比例进行比较。标本将尽可能从洛杉矶SEER残留组织库获得（第1阶段）。在征得患者同意后，将直接从医院获得额外的标本（第二阶段）。将制备包含肿瘤标本核心或样本的多肿瘤和/或组织微阵列，并将其连接到已确定的SEER数据（III期）。该研究资源将提供给NCI作为研究HIV/AIDS阳性和阴性癌症患者肿瘤标志物谱差异的研究资源。NCI艾滋病组织资源将是完成资源的记录之家。出于保密目的，洛杉矶SEER登记处将维护将标本编号与标识符链接的文件。包括洛杉矶SEER RTR和NCI人员在内的咨询委员会将共同审查使用所得生物标本收集的申请。

The Los Angeles SEER Residual Tissue Repository (RTR) will produce a tissue-based resource for research purposes consisting of cancer tumor specimens from HIV/AIDS patients and similar cancer tumor specimens from patients without HIV/AIDS in a multi-tumor block. HIV/AIDS patients will be identified from the previous Los Angeles County Department of Health Services HIV/AIDS ¿USC Cancer Surveillance Program database linkage, and also from a new linkage proposed for this coming year. The objective is to develop a collection of biospecimens 970 cancer patients. The following types of cancers specimens will be targeted for cases with HIV/AIDS: melanoma (n-30), Hodgkin lymphoma (n=30), non-Hodgkin lymphoma (n=200), lung cancer (n=50), cervical cancer (n=40), and anal cancer (n=40). Cancer patients unaffected by HIV/AIDS but with similar cancers will also be selected for comparison with a 2:1 matching ratio with the exception of non-Hodgkin lymphoma cancers will also be selected for comparison with a 1:1 matching ratio,. Specimens will be obtained from the Los Angeles SEER Residual Tissue Repository to the extent possible (Phase 1). Additional specimens will be obtained directly from hospitals after obtaining consent from patients (Phase 2). Multi-tumor and/or tissue microarrays containing cores or samples of the tumor specimen will be prepared and linked to deidentified SEER data (Phase III). This research resource will made available to NCI as a research resource to study differences in tumor marker profiles between HIV/AIDS positive and negative cancer patients. The NCI AIDS Tissue Resource will be the home of record for the completed resource. For confidentiality purposes, the Los Angeles SEER registry will maintain files that link specimen numbers to identifiers. An advisory board that includes Los Angeles SEER RTR and NCI personnel will co-review applications to use the resulting biospecimens collection.